Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ: SUPN · IEX Real-Time Price · USD
30.44
+0.36 (1.18%)
May 2, 2024, 12:29 PM EDT - Market open
Supernus Pharmaceuticals Employees
Supernus Pharmaceuticals had 652 employees on December 31, 2023. The number of employees increased by 40 or 6.54% compared to the previous year.
Employees
652
Change (1Y)
40
Growth (1Y)
6.54%
Revenue / Employee
$931,781
Profits / Employee
$2,018
Market Cap
1.67B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 652 | 40 | 6.54% |
Dec 31, 2022 | 612 | 37 | 6.43% |
Dec 31, 2021 | 575 | 12 | 2.13% |
Dec 31, 2020 | 563 | 99 | 21.34% |
Dec 31, 2019 | 464 | 16 | 3.57% |
Dec 31, 2018 | 448 | 26 | 6.16% |
Dec 31, 2017 | 422 | 59 | 16.25% |
Dec 31, 2016 | 363 | 19 | 5.52% |
Dec 31, 2015 | 344 | 35 | 11.33% |
Dec 31, 2014 | 309 | 74 | 31.49% |
Dec 31, 2013 | 235 | 42 | 21.76% |
Dec 31, 2012 | 193 | 124 | 179.71% |
Dec 31, 2011 | 69 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Addus HomeCare | 34,846 |
Myriad Genetics | 2,700 |
Zai Lab | 2,175 |
NeoGenomics | 2,100 |
Taro Pharmaceutical Industries | 1,554 |
Beam Therapeutics | 507 |
Harmony Biosciences Holdings | 246 |
Inhibrx | 172 |
SUPN News
- 1 hour ago - Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors - Business Wire
- 16 hours ago - INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors - Business Wire
- 1 day ago - Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story - GlobeNewsWire
- 2 days ago - The Law Offices of Frank R. Cruz Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors - Business Wire
- 4 days ago - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN - PRNewsWire
- 7 days ago - Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 - GlobeNewsWire
- 24 days ago - Supernus Provides Regulatory Update for SPN-830 - GlobeNewsWire
- 2 months ago - Supernus to Participate in Two Upcoming Investor Conferences - GlobeNewsWire